# Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

> **NCT00290615** · PHASE2 · COMPLETED · sponsor: **Herbert Hurwitz** · enrollment: 30 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** cetuximab
- **DRUG:** capecitabine
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00290615
- **Lead sponsor:** Herbert Hurwitz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-01
- **Final completion:** 2011-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290615, "Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00290615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*